Vertex - wie geht es weiter? - 500 Beiträge pro Seite

[BioMatt]

Im Moment scheint es der VRTX nicht so besonders gut zu gehen. Charttechnisch hat sich, mit Blick auf den Jahreschart, eine Schulter-Kopf-Schulter Formation gebildet.Woraus man auf weiter fallende Kurse schließen könnte. Mit knapp 60$ wird auch noch mal die 200-Tage-Linie getestet, hält sie nicht, dann könnte es noch bis in den Bereich von 40$ gehen. Hält sie allerdings, besteht die Möglichkeit der Bildung eines doppelten Bodens.
Fundamental läuft es im Prinzip alles nach Plan.Ein Produkt am Markt, das Erreichen weiterer Testphasen und natürlich die Pipeline.

Wollen wir das Beste hoffen!
MfG Matt

[dakinky]

Thursday January 4, 8:31 am Eastern Time

Press Release
SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Announces Start of Phase II Clinical Trial of VX-745 for Rheumatoid Arthritis

CAMBRIDGE, Mass., Jan. 4 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - news) announced today the commencement of a dose-ranging Phase II clinical trial with VX-745, a small molecule inhibitor of p38 MAP kinase, in patients with rheumatoid arthritis. Vertex is a leader in the discovery and clinical development of p38 MAP kinase inhibitors, which have the potential to be a powerful new class of oral anti-inflammatory medicines that reduce cytokine activity through a novel mechanism of action.
* (Photo: http://www.newscom.com/cgi-)bin/prnh/20000119/VERTEXLOGO

``The study announced today is designed to allow us to evaluate the clinical activity of a p38 MAP kinase inhibitor over a three-month dosing period,`` said John J. Alam, M.D., Senior Vice President for Drug Evaluation and Approval. ``Recent advancements in the treatment of rheumatoid arthritis, which demonstrate that TNF alpha inhibition is an important strategy for controlling disease progression, indicate significant potential for a well- tolerated, oral p38 MAP kinase inhibitor.``

P38 MAP kinase regulates the production of two cytokines, TNF alpha and IL-1, which have been implicated in a range of inflammatory diseases. In addition to rheumatoid arthritis, p38 MAP kinase inhibitors may play a future role in the treatment of heart failure, stroke, and other diseases. In tandem with the development of VX-745 as a lead clinical candidate for the treatment of rheumatoid arthritis, Vertex significantly broadened its p38 MAP kinase program in 2000 by advancing two additional, distinct p38 MAP kinase inhibitors, VX-954 and VX-702, into preclinical development. Vertex Pharmaceuticals holds development and commercial rights in the United States and Europe for its p38 MAP kinase inhibitors. Kissei Pharmaceutical Co., Ltd. of Matsumoto-City, Japan is Vertex`s partner for developing p38 MAP kinaseinhibitors in Japan and certain Asian countries. In December 2000, Kissei made a $1 million milestone payment to Vertex related to the start of preclinical testing of VX-702.

The randomized, double-blind, placebo-controlled trial announced today will test two different doses of VX-745 in a total of approximately 135 adult patients. The trial will explore the clinical activity and tolerability of escalating doses of VX-745 when given as monotherapy for three months. The trial will enroll patients who have active rheumatoid arthritis and are not responding adequately to their current therapy. The trial will evaluate objective clinical response rates, self-reported patient health assessments, and pharmacodynamic markers of drug activity.

The Company is in the final stages of providing clinical trial material for approximately 35 clinical centers in the United States that are scheduled to begin screening and enrolling patients. The trial is expected to be completed in 2001. In 2000, Vertex completed a one-month, pilot Phase II clinical trial in patients with rheumatoid arthritis.

Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex has 12 drug candidates in development to treat viral diseases, inflammation, cancer, autoimmune diseases, and cardiovascular and neurological disorders. Vertex has created its pipeline using a proprietary, information-intensive approach to drug design that integrates multiple technologies in biology, chemistry and biophysics, aimed at increasing the speed and success rate of drug discovery. Vertex`s first approved product is Agenerase(TM) (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with GlaxoSmithKline.

SAB 101

Vertex will adopt Staff Accounting Bulletin No. 101, or SAB 101, as of the quarter ended December 31, 2000. SAB 101 affects companies that engage in strategic alliances, such as that between Vertex and Kissei. The net effect of SAB 101 will be to defer revenue recognition for some portion of the amounts previously received by Vertex under its contract partnerships into future accounting periods. Vertex will record the cumulative effect of this change in accounting principle as of January 1, 2000. The implementation of SAB 101 is expected to have a material effect on the reported financial results for the year ended December 31, 2000.

This press release contains forward-looking statements about Vertex`s p38 MAP kinase inhibitor program and the drug candidate VX-745, including statements regarding expected clinical development activities, the therapeutic potential of p38 MAP kinase inhibitors, and the commercial opportunities in the treatment of rheumatoid arthritis. While management makes its best efforts to be accurate in making forward-looking statements, any such statements are subject to risks and uncertainties that could cause Vertex`s actual results to vary materially. Risk factors include uncertainties relating to the ability of Vertex to establish the safety and efficacy of VX- 745 in this and other planned clinical trials, the possibility of delays in clinical trials as a result of manufacturing and packaging of clinical trial material or slower than anticipated patient enrollment among other things, and uncertainties relating to Vertex`s ability to obtain regulatory approval for VX-745 and market the drug successfully.

Vertex`s press releases are available at www.vpharm.com, or by fax-on- demand at [phone] - Code: 938395.

SOURCE: Vertex Pharmaceuticals Incorporated

[Brucky]

Müsst es nicht heissen:Vertex,Abgenix,Myriad,Celgenen,usw.-wie geht es weiter?
Bei allen Bio`s mit ner guten Pipeline sieht es z.Zt. nicht besonders aus.

[WallStreetVamp]

rein charttechnisch gesehen, sieht es mit den amerikanischen biotechs eh nicht grade sehr rosig aus.
ich rechne zunächst erstmal mit massiv fallenden kursen, was mich natürlich sehr erquickt, da mein geld zu 75 % dort angelegt ist.
zu vertex: diese firma ist nach wie vor eine perle untef den ami-biotechs und wird sich langfristig gesehen wie auch die meisten anderen firmen gut entwickeln. aber eben langfristig..., gell.

WSV

[BioMatt]

@WSV

Bin zu 90% in US-Biotech`s investiert und bin einer der wenigen, die NOCH keinen Buchverlust ausweist.
Meine Werte: Vertex, Impath, Affymetrix, Enzon - und bis auf Enzon bin ich auch noch von allen Werten überzeugt!
Ich denke, wenn die NASDAQ jetzt kurzfristig steigt,was sicherlich von den heute erscheinenden Arbeitsmarktdaten abhängt, dann könnten wir nochmal Glück haben! Ansonsten denke ich, liegst Du gar nicht so schlecht!

Auf bessere Zeiten!